Sugi Predict

Sugi Predict / Compounds / SCHEMBL340702

SCHEMBL340702

SCHEMBL340702

O=C(O)c1cccc2c1OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ CDK2 P24941 1/20 0.41
▸ MMP2 P08253 1/20 0.41
▸ FAAH O00519 1/20 0.41
▸ MAOB P27338 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ FABP3 P05413 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ FABP5 Q01469 1/20 0.40
▸ CTNNB1 P35222 1/20 0.40
▸ WNT3A P56704 1/20 0.40
▸ ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442138 1.00 KDM4C (0.52) KDM4CALDH1A1MAPK1GSK3BABCG2
Hydrochloric Acid SCHEMBL9236405 0.98 KDM4C (0.51) KDM4CALDH1A1MAPK1GSK3BABCG2
Biphenyl SCHEMBL27726506 0.93 KDM4C (0.48) KDM4CALDH1A1GSK3BABCG2ALOX15
SCHEMBL6206600 0.86 ABCG2 (0.44) KDM4CALDH1A1MAPK1GSK3BABCG2
SCHEMBL251991 0.85 KDM4E (0.56) ALDH1A1ALOX15KDM4EHPGDCTNNB1
SCHEMBL30220126 0.85 KDM4E (0.56) ALDH1A1ALOX15KDM4EHPGDCTNNB1
SCHEMBL23079145 0.83 GSK3B (0.42) KDM4CALDH1A1MAPK1GSK3BABCG2
SCHEMBL341608 0.83 GSK3B (0.42) KDM4CALDH1A1MAPK1GSK3BABCG2
SCHEMBL1720148 0.83 PARP1 (0.54) ALDH1A1MAPK1KDM4EPOLBLMNA
SCHEMBL340356 0.83 KDM4E (0.44) KDM4CALDH1A1GSK3BABCG2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 — — EP claimed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 — — US claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 — — US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 — — US claimed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US claimed
CN-116253838-A Graft copolymer for preparing binaural extraction tube and preparation method thereof 深圳市远景医疗器械模具有限公司 2023-06-13 — — CN claimed
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2023-03-07 — — US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 — — EP claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 — — WO claimed
US-20150307443-A1 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION BARUCH S BLUMBERG INST (US) 2015-10-29 — — US claimed
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 — — EP claimed
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2010-09-02 — — US claimed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 — — US claimed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 — — EP claimed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 — — EP claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 — — WO claimed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 — — WO claimed
EP-0711774-B1 Crystalline cephem-addition salts and process for their preparation AVENTIS PHARMA GMBH (DE) 2002-02-13 — — EP claimed
US-5747484-A BACTERICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1998-05-05 — — US claimed
EP-0198797-A2 Parasiticide CIBA-GEIGY AG (CH) 1986-10-22 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307443-A1 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION HAVCR2, PHB2, PHB1 KDM4C 1160/4885ALDH1A1 1013/4885MAPK1 4399/4885
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 KDM4C 4779/4885ALDH1A1 1738/4885MAPK1 3004/4885
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES CYP11B2, CYP11B1, BBC3 KDM4C 1746/4885ALDH1A1 15/4885MAPK1 526/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 KDM4C 4779/4885ALDH1A1 1738/4885MAPK1 3004/4885
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 KDM4C 647/4885ALDH1A1 702/4885MAPK1 1726/4885
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC3 KDM4C 4774/4885ALDH1A1 1717/4885MAPK1 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.